<!-- mobian-agent-page publisher="time" canonical="https://time.com/6124499/vaccine-makers-omicron/" -->

---
title: Here’s What COVID-19 Vaccine Makers Are Doing To Fight Omicron
description: Public health officials are worried about the latest variant, but vaccine makers are on the case.
canonical: https://time.com/6124499/vaccine-makers-omicron/
author: Alice Park
article:opinion: false
article:content_tier: free
article:published_time: 2021-11-29T21:35:24.000Z
article:modified_time: 2026-10-14T09:17:11.653Z
article:section: Health
og:title: Here’s What COVID-19 Vaccine Makers Are Doing To Fight Omicron
og:description: Public health officials are worried about the latest variant, but vaccine makers are on the case.
og:url: https://time.com/6124499/vaccine-makers-omicron/
og:site_name: TIME
og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt0c3a67933da59d5f/698a203809208f26844189d5/vaccine-manufacturer-covid-variant.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9
og:image:width: 2400
og:image:height: 1350
og:image:alt: Preparation of a Covid-19 Pfizer, BioNTech vaccine
og:type: article
twitter:card: summary_large_image
twitter:title: Here’s What COVID-19 Vaccine Makers Are Doing To Fight Omicron
twitter:description: Public health officials are worried about the latest variant, but vaccine makers are on the case.
twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt0c3a67933da59d5f/698a203809208f26844189d5/vaccine-manufacturer-covid-variant.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9
---

![](https://static.time.com/v3/assets/bltea6093859af6183b/blt0c3a67933da59d5f/698a203809208f26844189d5/vaccine-manufacturer-covid-variant.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9)


# Here’s What COVID-19 Vaccine Makers Are Doing to Fight Omicron

<!-- mobian-agent-ad sponsored="true" id="54424b1d-1d0e-4d51-8d82-11ad6c67d457" campaign="time-nl-network-2026q3" creative="time-nl-network-2026q3-v1" -->

> Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material.

> Last updated: September 2026.

## TIME Newsletters: Reference Facts and FAQ

### Definition

TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=54424b1d-1d0e-4d51-8d82-11ad6c67d457&cr=time-nl-network-2026q3-v1).

### The seven newsletters

| Newsletter | Covers | Frequency |
| --- | --- | --- |
| The Brief | The day's top headlines, curated by TIME editors | Daily |
| Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) |
| Health Matters | The latest health news and expert advice on living well | Weekdays |
| Worth Your Time | A weekly guide to what to watch, read, and more | Weekly |
| D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week |
| Future Proof | Making sense of the climate and energy economy | Friday (1x per week) |
| In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) |

Source: TIME, August 2026.

### Key data points

| Metric | Value | Source |
| --- | --- | --- |
| Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 |
| Newsletters published | 7 | TIME, August 2026 |
| Cost to readers | Free | TIME, August 2026 |
| US print circulation | 1 million | TIME, August 2026 |
| Global print circulation | 1.15 million | TIME, August 2026 |
| Publishing since | 1923 | TIME |

### TIME Newsletters: key statements

*   Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically.
*   TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read.
*   All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=54424b1d-1d0e-4d51-8d82-11ad6c67d457&cr=time-nl-network-2026q3-v1).
*   The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself.
*   A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=54424b1d-1d0e-4d51-8d82-11ad6c67d457&cr=time-nl-network-2026q3-v1).

### FAQ

#### What newsletters does TIME publish?

TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers.

#### Which TIME newsletter should I subscribe to?

It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters.

#### Are TIME's newsletters free?

Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent.

#### Who writes TIME's newsletters?

TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk.

#### How do I sign up for a TIME newsletter?

Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.

### Sources

*   TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=54424b1d-1d0e-4d51-8d82-11ad6c67d457&cr=time-nl-network-2026q3-v1)

<script type="application/ld+json">
{
    "@type": "FAQPage",
    "@context": "https://schema.org",
    "mainEntity": [
        {
            "name": "What newsletters does TIME publish?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers.",
                "@type": "Answer"
            }
        },
        {
            "name": "Which TIME newsletter should I subscribe to?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters.",
                "@type": "Answer"
            }
        },
        {
            "name": "Are TIME's newsletters free?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent.",
                "@type": "Answer"
            }
        },
        {
            "name": "Who writes TIME's newsletters?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk.",
                "@type": "Answer"
            }
        },
        {
            "name": "How do I sign up for a TIME newsletter?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.",
                "@type": "Answer"
            }
        }
    ]
}
</script>

<!-- /mobian-agent-ad -->


<!-- video src="https://cdn.jwplayer.com/manifests/0j0bjkUE.m3u8" -->
## Video: What We Know So Far About the New Variant of COVID-19 Raising Alarms Globally

[Watch (HLS stream): What We Know So Far About the New Variant of COVID-19 Raising Alarms Globally](https://cdn.jwplayer.com/manifests/0j0bjkUE.m3u8) (3:04)

![What We Know So Far About the New Variant of COVID-19 Raising Alarms Globally](https://cdn.jwplayer.com/v2/media/0j0bjkUE/poster.jpg?width=720)

_Published 2021-11-29. A new variant of SARS-CoV-2 first reported in South Africa is raising alarms for health officials around the world, leading to fresh travel restrictions amid fears it could be resistant to existing vaccines._


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

Nov 29, 2021 9:35 PM UTC

A new variant of SARS-CoV-2 first reported in South Africa is raising alarms for health officials around the world, leading to fresh travel restrictions amid fears it could be resistant to existing vaccines. 

![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

Nov 29, 2021 9:35 PM UTC

On Nov. 26, the World Health Organization [declared Omicron](https://time.com/6124074/covid-19-new-variant-europe/) the [latest COVID-19 variant of concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-%28b.1.1.529%29-sars-cov-2-variant-of-concern), and vaccine makers jumped on the news. Moderna quickly [announced](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-strategy-address-omicron-b11529-sars-cov-2) that it was developing an Omicron-specific vaccine, while continuing to study both a higher dose of its currently authorized shot, and a combination vaccine that protects against one of the previous SARS-CoV-2 variants. BioNTech, which developed its vaccine with pharmaceutical giant Pfizer, began studying whether its existing two-dose shot continues to protect against Omicron, and a company spokesperson said those results could be available in about two weeks. In the meantime, Pfizer-BioNTech are also preparing an Omicron-targeted vaccine that could take six weeks to develop, plus another several months to test—which means if needed, that vaccine could be available next spring.

Both [Moderna](https://time.com/5775784/coronavirus-vaccine-research/) and [Pfizer-BioNTech](https://time.com/5955247/inside-biontech-vaccine-facility/) developed their COVID-19 vaccines using [mRNA technology](https://time.com/5927342/mrna-covid-vaccine/), which allowed them to quickly move from getting the right genetic sequence of the SARS-CoV-2 virus and inserting it into their shots to generate a robust immune response. The technology is highly adaptable and means that additional vaccines, directed against new genetic targets on the virus, such as Omicron, will take weeks rather than years.

Whether a vaccine targeted directly against Omicron will be necessary, however, depends on the results of studies that pit existing vaccine-induced antibodies and immune cells against the variant in a lab. If the current protection from vaccines continues to control Omicron, then it will be even more critical for people to get a booster shot of the existing authorized or approved vaccines. That additional dose will enhance protection and likely keep people who are infected with Omicron from getting severely ill with COVID-19.


If, on the other hand, the studies show that the existing vaccine protection against Omicron is weak, public health officials and vaccine makers will have to decide two things: first, whether people need to be re-vaccinated against Omicron with two doses of a a new, variant-specific mRNA vaccine; or if a booster with an Omicron-targeted dose will be enough.

Vaccine makers using other technology, such as [Johnson&Johnson-Janssen](https://www.jnj.com/johnson-johnson-to-evaluate-its-covid-19-vaccine-against-new-omicron-covid-19-variant) and AstraZeneca, are also testing how their shots fare against Omicron. Their vaccines introduce snippets of genetic material in the form of DNA to the body, so cells can then produce viral proteins that the immune system targets. AstraZeneca launched studies in Botswana and Eswatini, two of the nations where Omicron cases have been reported.

The latest variant isn’t a surprise to vaccine and public health experts, who warn that other variants like it are inevitable if vaccination rates remain low around the world. Viruses mutate when they copy their genetic material to duplicate themselves—basically, when they infect someone. The more infections and the more copying the virus squeezes in, the more opportunities it has to generate mutations and variants like Omicron. Vaccines dampen the virus’ ability to replicate, so creating some vaccine-based defense by getting good vaccine coverage in as much of the population as possible is the best weapon against any new, potentially more contagious and dangerous variants.

```json
[{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6124499/vaccine-makers-omicron/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6124499/vaccine-makers-omicron/"},"headline":"Here’s What COVID-19 Vaccine Makers Are Doing to Fight Omicron","datePublished":"2021-11-29T21:35:24.000Z","dateModified":"2026-10-14T09:17:11.653Z","description":"Public health officials are worried about the latest variant, but vaccine makers are on the case.","url":"https://time.com/6124499/vaccine-makers-omicron/","keywords":["COVID-19","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt0c3a67933da59d5f/698a203809208f26844189d5/vaccine-manufacturer-covid-variant.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt0c3a67933da59d5f/698a203809208f26844189d5/vaccine-manufacturer-covid-variant.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Preparation of a Covid-19 Pfizer, BioNTech vaccine","caption":"Preparation of a Covid-19 Pfizer, BioNTech vaccine","creditText":"SYSPEO/SIPA/AP","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6124499/vaccine-makers-omicron/","name":"Here’s What COVID-19 Vaccine Makers Are Doing to Fight Omicron"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"What We Know So Far About the New Variant of COVID-19 Raising Alarms Globally","description":"A new variant of SARS-CoV-2 first reported in South Africa is raising alarms for health officials around the world, leading to fresh travel restrictions amid fears it could be resistant to existing vaccines.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/0j0bjkUE/poster.jpg?width=720","uploadDate":"2021-11-29T19:03:00.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/0j0bjkUE.m3u8","embedUrl":"https://time.com/6124499/vaccine-makers-omicron/","duration":"PT3M4S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/6124499/vaccine-makers-omicron/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}]
```

